Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

0
Player Avatar dunloggin (71.99) Submitted: 10/18/2010 11:11:16 AM : Outperform Start Price: $3.12 SNTS Score: +79.94

Taking a flier on this one.

Featured Broker Partners


Advertisement